The global pharmaceutical contract development and manufacturing organization (CDMO) market is witnessing substantial growth, driven by the increasing outsourcing of drug development and manufacturing processes by pharmaceutical companies. As the complexity of drug development rises and cost pressures intensify, CDMOs are becoming essential partners in accelerating time-to-market and improving...

Market Overview & Size The global pharmaceutical CDMO industry has moved well past its early role as a low-cost manufacturing backup option — it is now a structural pillar of how new drugs reach patients. According to Grand View Research, the market was valued at USD 166.0 billion in 2025 and is estimated to reach USD 177.6 billion in 2026. From there, it is projected to climb to USD...

The demand for Small Molecules Innovator CDMO services is experiencing an unprecedented surge, with projections indicating a market size reaching USD 80.04 billion by 2035. This represents a compound annual growth rate (CAGR) of 4.27%, highlighting a robust trajectory from the 2024 valuation of USD 50.53 billion. Factors like the increasing complexity of drug formulations and the shift towards...

The Germany Pharmaceutical CDMO Market growth continues to accelerate as pharmaceutical quality control and analytical testing outsourcing becomes standard practice for ensuring regulatory compliance and product safety. With increasing complexity of biologics characterization, growing regulatory expectations for comprehensive impurity profiling, and expanding need for stability testing across...

The global oral solid dosage contract manufacturing market is becoming an increasingly important part of the pharmaceutical manufacturing ecosystem as drug developers and pharmaceutical companies turn to specialized contract development and manufacturing organizations (CDMOs) for formulation development, scale-up, and commercial production. Rising outsourcing activity, growing generic drug...